Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3004738 | 1.00 | REN (0.55) | RENCYP3A4 | |
| SCHEMBL3008220 | 0.92 | REN (0.47) | RENCYP3A4 | |
| SCHEMBL8107671 | 0.88 | REN (0.46) | RENCYP3A4 | |
| SCHEMBL3005071 | 0.85 | REN (0.42) | RENCYP3A4 | |
| SCHEMBL3005069 | 0.85 | REN (0.42) | RENCYP3A4 | |
| SCHEMBL13242431 | 0.83 | REN (0.42) | REN | |
| SCHEMBL499056 | 0.82 | REN (0.55) | RENCYP3A4 | |
| SCHEMBL499055 | 0.82 | REN (0.55) | RENCYP3A4 | |
| SCHEMBL4753059 | 0.82 | NPC1 (0.40) | RENCYP3A4 | |
| SCHEMBL499126 | 0.81 | REN (0.53) | RENCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190829-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS INC | 2010-07-29 | — | — | US | claimed |
| WO-2008156828-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2008-12-24 | — | — | WO | claimed |
| US-20100190829-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS INC | 2010-07-29 | — | — | US | disclosed |
| US-20100190829-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS INC | 2010-07-29 | — | — | US | disclosed |
| US-20100190829-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS INC | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190829-A1 | RENIN INHIBITORS | ACE, REN, DNPEP | REN 2/4885CYP3A4 3133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.